spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  galectin 

 HSMN NewsFeed - 30 Oct 2018
G3 Pharmaceuticals Signs Exclusive License and Option Agreement for Treating Diastolic Heart Failure (HFpEF) by Inhibiting Galectin-3
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 15 Oct 2013
La Jolla Pharmaceutical Company Announces Appointment of Two Additional Independent Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jul 2013
La Jolla Pharmaceutical Company Receives Orphan Designation From FDA
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 9 May 2013
BG Medicine Appoints Dr. Paul Sohmer as Chief Executive Officer
Diagnostics Cardiology Personnel
 HSMN NewsFeed - 24 Apr 2013
Launch of the avert-AF Scientific Initiative to Develop a Drug Treatment for the Prevention of Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 Jan 2013
Galectin Therapeutics Appoints Industry Veteran Rex Horton as Executive Director of Regulatory Affairs and Quality Assurance
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Jan 2013
La Jolla Pharmaceutical Company Adds to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Dec 2012
BG Medicine Obtains CE Mark for CardioSCORE(TM) Test in Europe
Diagnostics Cardiology Regulatory
 HSMN NewsFeed - 11 Sep 2012
BG Announces Key Additions to Senior Management Team
Diagnostics Cardiology Personnel
 HSMN NewsFeed - 2 Jul 2012
BG Medicine, Inc. Appoints Bill Densel, General Manager, CardioSCORE
Diagnostics Cardiology Personnel
 HSMN NewsFeed - 20 Jan 2012
La Jolla Pharmaceutical Company Acquires GCS-100, a First-in-Class Galectin-3 Antagonist
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 9 Jan 2012
BG Medicine, Inc. Appoints Eric Bouvier as Chief Executive Officer
Diagnostics Personnel
 HSMN NewsFeed - 28 Jun 2011
BG Medicine, Inc. Names Stephen R. Miller Chief Commercial Officer
Diagnostics Personnel
 HSMN NewsFeed - 2 Jun 2011
Galectin Therapeutics Announces the Appointment of Kevin Freeman and John Mauldin to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Mar 2011
Pro-Pharmaceuticals Names Peter G. Traber, M.D., Former GlaxoSmithKline Chief Medical Officer & President Emeritus of Baylor College of Medicine, President & Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Nov 2010
BG Medicine Announces FDA 510(k) Clearance of its Galectin-3 Test for Use in Patients with Chronic Heart Failure
Diagnostics Cardiology FDA
 HSMN NewsFeed - 26 Apr 2010
Inverness Medical Innovations and BG Medicine to Develop Galectin-3 Test for Inverness' Triage(R) Meter
Diagnostics Devices Cardiology
 HSMN NewsFeed - 29 Mar 2010
Pro-Pharmaceuticals Licenses to PROCAPS S.A. Exclusive Marketing and Distribution Rights to Commercialize DAVANAT(R) to Treat Cancer in Colombia, South America
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 17 Nov 2009
Abbott to Develop New Heart Failure Test on ARCHITECT(R) Immunochemistry Diagnostics Platform
Diagnostics Cardiology
 HSMN NewsFeed - 17 Jul 2009
Pro-Pharmaceuticals Prevails in Trade Secret Lawsuit
Biopharmaceuticals Oncology Litigation
 HSMN NewsFeed - 29 Jan 2009
FDA Provides Clear Path to NDA Submission for Pro-Pharmaceuticals’ DAVANAT(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Mar 2008
Pro-Pharmaceuticals Announces DAVANAT(R) Regimen Approved to Treat Breast Cancer Patient
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Mar 2008
Pro-Pharmaceuticals DAVANAT(R) Extends Median Survival 6.7 Months for End-Stage Colorectal Cancer Patients After All Other Treatments Failed
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Feb 2008
New Data Shows DAVANAT(R) Extends Survival of End-Stage Colorectal Cancer Patients More Than 6 Months
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Aug 2007
Pro-Pharmaceuticals Announces ''Compassionate Use'' IND for DAVANAT(R) to Treat Biliary Cancer Patient
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jul 2007
Pro-Pharmaceuticals Updates Progress of Clinical Trials & DAVANAT(R) 505 (b)(2) Filings
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 12 Apr 2007
Pro-Pharmaceuticals Plans to Submit a New Drug Application for DAVANAT(R), as a Functional Excipient, with 5-FU to Treat Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2007
Pro-Pharmaceuticals Receives Letter from the FDA for New Drug Application for DAVANAT(R)/ 5-FU
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Apr 2007
Pro-Pharmaceuticals Announces Tampa General Hospital Dosing Patients with DAVANAT(R)/5-FU in Phase II, First Line, Advanced Biliary Cancer Clinical Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Feb 2007
Pro-Pharmaceuticals Submits Orphan Drug Status Application to European Medicines Agency Co-administration of DAVANAT(R) with 5-FU to Treat Cholangiocarcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Feb 2007
Pro-Pharmaceuticals Meeting Scheduled with the FDA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Feb 2007
Pro-Pharmaceuticals' Begins Process of New Drug Application Submission with the FDA for Co-administration of DAVANAT(R) with 5-FU in Cancer Patients
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
galectin
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!